anti-CD7 CAR-T

BIOLOGICAL2 trials

Sponsors

Zhejiang University, Institute of Hematology & Blood Diseases Hospital, China

Conditions

CD7+ Acute LeukemiaCD7+ LymphomaHematological Malignancies

Phase 1

Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy

Zhejiang UniversityCD7+ Acute Leukemia, CD7+ Lymphoma

Start: 2021-04-01End: 2025-12-30Target: 81Updated: 2023-12-06

Phase 2

CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies

CompletedNCT05454241

Institute of Hematology & Blood Diseases Hospital, ChinaHematological Malignancies

Start: 2022-09-07End: 2024-08-31Updated: 2025-03-13

Related Papers

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

2026-07-03

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

Blood2025-11-03

A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)

Blood2025-11-03

CD7-targeted universal CAR T-cell therapy in relapsed or refractory (R/R) acute myeloid leukemia (AML): Clinical results from CTD401/402 studies

Blood2025-11-03

Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis

New England Journal of Medicine2024-04-2490 citations

Gene-Edited Universal CD7 Chimeric Antigen Receptor T Cells for Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Blood2023-11-024 citations

Neither Conditioning Chemotherapy Nor GvHD-Prophylaxis: CD7 CAR-T Treatment Bridging to Haplo-HSCT

Blood2023-11-023 citations